J&J's MonumenTAL-6 results add to the growing body of evidence touting Talvey and Tecvayli’s use in earlier multiple myeloma treatment lines.

China is rapidly overtaking the US in global oncology clinical trials, accounting for more than half of late-stage study activity by 2025.

Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded in type 2 diabetes and obesity. Marking the four ...

The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.

Devonian Health Group has received authorisation from Health Canada for its CTA to begin a Phase II/III study of Thykamine cream to treat mild-to-moderate atopic dermatitis in paediatric patients.

Biogen said that the 60mg cohort saw greater benefit than either of the115mg cohorts. Credit: Tada Images / Shutterstock.com Biogen’s stock has dropped after it released mixed data on its ...

The Phase III trial failed to meet its co-primary endpoints or any of its key secondary endpoints. Credit: Ton Photographer 4289 / Shuttertock.com Kolon TissueGene’s stock has dropped after a Phase ...

Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors.

Trellis Bioscience has closed a $9m Series C round to support the completion of its ongoing Phase II trial evaluating calpurbatug for chronic PJI.

When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.

GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.

Arrowhead's EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.